Current and historical daily PE Ratio for Wuhan Easy Diagnosis Biomedicine Co Ltd (
) from 2018 to Sep 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Wuhan Easy Diagnosis Biomedicine stock (SZSE:002932) PE ratio as of Sep 23 2024 is 128.83.
More Details
Wuhan Easy Diagnosis Biomedicine Co Ltd (SZSE:002932) PE Ratio (TTM) Chart
Wuhan Easy Diagnosis Biomedicine Co Ltd (SZSE:002932) PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Total 1208
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Wuhan Easy Diagnosis Biomedicine PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-09-23 | 128.8 | 2024-07-18 | 140.2 |
| 2024-09-20 | 129.2 | 2024-07-17 | 140.1 |
| 2024-09-19 | 130.5 | 2024-07-16 | 138.8 |
| 2024-09-18 | 130.3 | 2024-07-15 | 140.0 |
| 2024-09-13 | 130.6 | 2024-07-12 | 142.8 |
| 2024-09-12 | 132.4 | 2024-07-11 | 142.4 |
| 2024-09-11 | 133.3 | 2024-07-10 | 136.9 |
| 2024-09-10 | 134.7 | 2024-07-09 | 136.3 |
| 2024-09-09 | 135.1 | 2024-07-08 | 135.0 |
| 2024-09-06 | 134.3 | 2024-07-05 | 140.2 |
| 2024-09-05 | 137.8 | 2024-07-04 | 136.5 |
| 2024-09-04 | 135.3 | 2024-07-03 | 138.6 |
| 2024-09-03 | 136.3 | 2024-07-02 | 140.3 |
| 2024-09-02 | 135.2 | 2024-07-01 | 141.6 |
| 2024-08-30 | 138.4 | 2024-06-28 | 140.1 |
| 2024-08-29 | 136.8 | 2024-06-27 | 120.9 |
| 2024-08-28 | 137.0 | 2024-06-26 | 125.0 |
| 2024-08-27 | 136.0 | 2024-06-25 | 120.9 |
| 2024-08-26 | 136.8 | 2024-06-24 | 122.3 |
| 2024-08-23 | 136.1 | 2024-06-21 | 127.7 |
| 2024-08-22 | 137.6 | 2024-06-20 | 127.3 |
| 2024-08-21 | 140.9 | 2024-06-19 | 128.2 |
| 2024-08-20 | 144.5 | 2024-06-18 | 129.9 |
| 2024-08-19 | 148.1 | 2024-06-17 | 131.7 |
| 2024-08-16 | 150.0 | 2024-06-14 | 131.6 |
| 2024-08-15 | 141.8 | 2024-06-13 | 132.3 |
| 2024-08-14 | 139.2 | 2024-06-12 | 135.4 |
| 2024-08-13 | 141.7 | 2024-06-11 | 134.6 |
| 2024-08-12 | 148.0 | 2024-06-07 | 134.6 |
| 2024-08-09 | 140.5 | 2024-06-06 | 132.0 |
| 2024-08-08 | 143.1 | 2024-06-05 | 132.6 |
| 2024-08-07 | 140.7 | 2024-06-04 | 131.6 |
| 2024-08-06 | 140.8 | 2024-06-03 | 132.4 |
| 2024-08-05 | 136.1 | 2024-05-31 | 135.1 |
| 2024-08-02 | 138.5 | 2024-05-30 | 133.6 |
| 2024-08-01 | 137.4 | 2024-05-29 | 134.3 |
| 2024-07-31 | 138.0 | 2024-05-28 | 133.5 |
| 2024-07-30 | 133.6 | 2024-05-27 | 136.2 |
| 2024-07-29 | 133.1 | 2024-05-24 | 135.6 |
| 2024-07-26 | 133.9 | 2024-05-23 | 136.6 |
| 2024-07-25 | 133.3 | 2024-05-22 | 140.7 |
| 2024-07-24 | 132.7 | 2024-05-21 | 139.9 |
| 2024-07-23 | 135.6 | 2024-05-20 | 142.4 |
| 2024-07-22 | 140.3 | 2024-05-17 | 142.3 |
| 2024-07-19 | 139.8 | 2024-05-16 | 141.6 |
Wuhan Easy Diagnosis Biomedicine Co Ltd (SZSE:002932) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Wuhan Easy Diagnosis Biomedicine Co Ltd
ISIN : CNE1000033Q7
Share Class Description:
SZSE:002932: Class ACompare
Compare
Traded in other countries / regions
002932.China IPO Date
2018-07-10Description
Wuhan Easy Diagnosis Biomedicine Co Ltd is engaged in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments and mobile ECG products. The company's product profile consists of Molecular diagnosis, Chemiluminescence, Blood gas analysis, and others. It also provides various other solutions such as Mingde Biomolecular Diagnostic Service Solution, Mingde Biothoracic Center Solution, POCT Solution, Remote ECG network construction solution, and others.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers